Related Experiment Videos
Differential expression of two ICAM-1 epitopes and LFA-1 chains in B-cell non-Hodgkin's lymphomas
A Vacca1, G Ranieri, D Ribatti
1Department of Biomedical Sciences and Human Oncology, University of Bari Medical School, Italy.
Insights
Expression defects in ICAM-1 and LFA-1 were observed in B-cell non-Hodgkin's lymphomas (B-NHL), correlating with malignancy grade. These changes may indicate tumor progression and help distinguish malignant from benign lymphoproliferations.
Area of Science:
- Immunology
- Hematology
- Oncology
Background:
- Intercellular Adhesion Molecule 1 (ICAM-1) and Leukocyte Function-associated Antigen 1 (LFA-1) are crucial for immune cell interactions.
- Aberrant expression of adhesion molecules is implicated in lymphoproliferative disorders.
Purpose of the Study:
- To investigate the expression patterns of ICAM-1 epitopes (Me14/D12, P3-58) and LFA-1 chains (alpha, beta) in B-cell non-Hodgkin's lymphomas (B-NHL).
- To correlate these expression profiles with the Working Formulation (WF) malignancy grade of B-NHL.
- To explore the potential role of these expression defects in B-NHL progression and differentiation.
Main Methods:
- Immunohistochemical analysis was performed on B-NHL and reactive lymphadenopathies.
- Expression levels of two distinct ICAM-1 epitopes and LFA-1 alpha and beta chains were assessed.
- Expression profiles were analyzed in relation to WF malignancy grade and specific B-NHL subtypes.
Main Results:
- A partial or total loss of ICAM-1 and/or LFA-1 expression was observed in all B-NHL, increasing with WF malignancy grade.
- High-grade B-NHL showed the most significant defects, including reduced detectability of ICAM-1 Me14/D12 and LFA-1 alpha, and decreased co-expression.
- Distinct ICAM-1 and LFA-1 profiles were noted among high-grade subtypes, with Burkitt's and lymphoblastic lymphomas showing complete loss, while large cell/immunoblastic lymphomas exhibited variable expression.
Conclusions:
- Expression defects of ICAM-1 and LFA-1 are associated with B-NHL progression and higher malignancy grades.
- These molecular alterations may serve as markers to differentiate malignant from benign lymphoproliferations.
- The distinct expression profiles in high-grade B-NHL subtypes suggest a link to specific normal B-cell differentiation stages.
Abstract:
B-cell non-Hodgkin's lymphomas (B-NHL) and B-cell areas of reactive lymphadenopathies were investigated immunohistochemically for expression of two distinct ICAM-1 epitopes, Me14/D12 and P3-58, and the LFA-1 alpha and beta chains. Partial or total loss of expression of one or both epitope(s) and/or chain(s) was evident in all B-NHL in function of increasing Working Formulation (WF) malignancy grade, with most defects in the high-grade tumors, namely the lowest detectability of the ICAM-1 Me14/D12 and LFA-1 alpha chain, the lowest co-expression of ICAM-1 epitopes and LFA-1 chains, and the most frequent simultaneous loss. The ICAM-1 and LFA-1 profiles overlapped within the low- and intermediate-grades, whereas striking differences between the high-grade subtypes were detected. Specifically, Burkitt's and lymphoblastic tumors always lost both epitopes and both chains. Large cell, immunoblastic tumors occasionally did so, and also showed either uncoordinated expression or co-expression of these constituents. It is suggested that expression defects of this type may help differentiate malignant from benign lymphoproliferations, and also be involved in the progression of B-NHL, since most are observed in high-grade tumors, whose ICAM-1 and LFA-1 profiles indicate that their subtypes are the expression of distinct normal B-cell differentiation stages.